Patents by Inventor Miki YAMAGUCHI

Miki YAMAGUCHI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210030020
    Abstract: A purpose of the present invention is to provide ice cream to which new oral texture is imparted. According to the embodiment of the present invention, ice cream is provided which contains high-amylose rice that has been cooked, in which the content ratio of the high-amylose rice is 0.1-20.0% by mass.
    Type: Application
    Filed: March 8, 2019
    Publication date: February 4, 2021
    Applicant: Yanmar Power Technology Co., Ltd.
    Inventors: Miki YAMAGUCHI, Kuniyasu TSUCHIYA
  • Publication number: 20200321544
    Abstract: As a novel substance having a novel skeleton, an organometallic complex with high emission efficiency which achieves improved color purity by a reduction of half width of an emission spectrum is provided. One embodiment of the present invention is an organometallic complex in which a ?-diketone and a six-membered heteroaromatic ring including two or more nitrogen atoms inclusive of a nitrogen atom that is a coordinating atom are ligands. In General Formula (G1), X represents a substituted or unsubstituted six-membered heteroaromatic ring including two or more nitrogen atoms inclusive of a nitrogen atom that is a coordinating atom. Further, R1 to R4 each represent a substituted or unsubstituted alkyl group having 1 to 6 carbon atoms.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 8, 2020
    Applicant: Semiconductor Energy Laboratory Co., Ltd.
    Inventors: Hideko Inoue, Tomoya YAMAGUCHI, Hiromi SEO, Satoshi SEO, Kunihiko SUZUKI, Miki KANAMOTO
  • Patent number: 10693085
    Abstract: A light-emitting element with a light-emitting substance comprising an organometallic complex. The organometallic complex having a structure represented by General Formula (G0). In the formula, X represents a substituted or unsubstituted six-membered heteroaromatic ring including two or more nitrogen atoms inclusive of a nitrogen atom that is a coordinating atom. Further, R1 and R2 each represent an alkyl group having 1 to 6 carbon atoms.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: June 23, 2020
    Assignee: Semiconductor Energy Laboratory Co., Ltd.
    Inventors: Hideko Inoue, Tomoya Yamaguchi, Hiromi Seo, Satoshi Seo, Kunihiko Suzuki, Miki Kanamoto
  • Patent number: 10545018
    Abstract: The purpose of the present invention is to provide a pattern measurement device which adequately evaluates a pattern formed by means of a patterning method for forming a pattern that is not in a photomask. In order to fulfil the purpose, the present invention suggests a pattern measurement device provided with a computation device for measuring the dimensions between patterns formed on a sample, wherein: the centroid of the pattern formed on the sample is extracted from data to be measured obtained by irradiating beams; a position alignment process is executed between the extracted centroid and measurement reference data in which a reference functioning as the measurement start point or measurement end point is set; and the dimensions between the measurement start point or the measurement end point of the measurement reference data, which was subjected to position alignment, and the edge or the centroid of the pattern contained in the data to be measured is measured.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: January 28, 2020
    Assignee: Hitachi High-Technologies Corporation
    Inventors: Satoru Yamaguchi, Norio Hasegawa, Akiyuki Sugiyama, Miki Isawa, Akihiro Onizawa, Ryuji Mitsuhashi
  • Patent number: 10356186
    Abstract: A system and method to estimate a location relating to a user who has not filled in information about the location in a profile field in social media such as a microblog. The system and method estimates association between a user in social media and a location includes the steps of acquiring a first content posted to the social media by a first user associated with a first location, determines regional localization of the first content on the basis of the first location, acquires a second content posted to the social media by a second user not associated with a location, determine the degree of a relationship between the first content and the second content, and associating the first location with the second user on the basis of the localization and the degree of the relationship.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: July 16, 2019
    Assignee: International Business Machines Corporation
    Inventors: Miki Enoki, Yohei Ikawa, Michiaki Tatsubori, Yuto Yamaguchi
  • Publication number: 20190144559
    Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.
    Type: Application
    Filed: January 24, 2019
    Publication date: May 16, 2019
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, SAPPORO MEDICAL UNIVERSITY
    Inventors: Toshinori Agatsuma, Shu Takahashi, Jun Hasegawa, Daisuke Okajima, Hirofumi Hamada, Miki Yamaguchi
  • Patent number: 10227417
    Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: March 12, 2019
    Assignees: DAIICHI SANKYO COMPANY, LIMITED, SAPPORO MEDICAL UNIVERSITY
    Inventors: Toshinori Agatsuma, Shu Takahashi, Jun Hasegawa, Daisuke Okajima, Hirofumi Hamada, Miki Yamaguchi
  • Publication number: 20180094073
    Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.
    Type: Application
    Filed: November 22, 2017
    Publication date: April 5, 2018
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, SAPPORO MEDICAL UNIVERSITY
    Inventors: Toshinori AGATSUMA, Shu TAKAHASHI, Jun HASEGAWA, Daisuke OKAJIMA, Hirofumi HAMADA, Miki YAMAGUCHI
  • Patent number: 9850312
    Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: December 26, 2017
    Assignees: DAIICHI SANKYO COMPANY, LIMITED, SAPPORO MEDICAL UNIVERSITY
    Inventors: Toshinori Agatsuma, Shu Takahashi, Jun Hasegawa, Daisuke Okajima, Hirofumi Hamada, Miki Yamaguchi
  • Publication number: 20160297890
    Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.
    Type: Application
    Filed: June 20, 2016
    Publication date: October 13, 2016
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, SAPPORO MEDICAL UNIVERSITY
    Inventors: Toshinori AGATSUMA, Shu TAKAHASHI, Jun HASEGAWA, Daisuke OKAJIMA, Hirofumi HAMADA, Miki YAMAGUCHI
  • Publication number: 20120237518
    Abstract: The present invention relates to a monoclonal antibody or an antibody fragment thereof, which binds to the extracellular region of human Trop-2 with high affinity and exhibits high ADCC activity and high antitumor activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which comprises the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent or a diagnostic agent using the antibody fragment thereof.
    Type: Application
    Filed: June 10, 2011
    Publication date: September 20, 2012
    Applicants: KYOWA HAKKO KIRIN CO., LTD, SAPPORO MEDICAL UNIVERSITY
    Inventors: Miki YAMAGUCHI, Kazunori Kato, Hirofumi HAMADA, Kazuyasu NAKAMURA, Yoshiyuki SUGIMOTO, Tsuguo KUBOTA, Masahiro IKEDA